DK2215121T3 - Anti-mesothelin-antistoffer og anvendelser deraf - Google Patents
Anti-mesothelin-antistoffer og anvendelser deraf Download PDFInfo
- Publication number
- DK2215121T3 DK2215121T3 DK08855189.0T DK08855189T DK2215121T3 DK 2215121 T3 DK2215121 T3 DK 2215121T3 DK 08855189 T DK08855189 T DK 08855189T DK 2215121 T3 DK2215121 T3 DK 2215121T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- gly
- thr
- leu
- val
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Isoleret humant antistof eller funktionelt fragment deraf, der omfatter en antigenbindende region, der er specifik for mesothelin ifølge SEQ ID NO: 370, hvor antistoffet eller det funktionelle fragment deraf genkender en epitop på mesothelin, der ikke er dækket af cancerantigen 125 (CA125), og hvor antistoffet eller det funktionelle fragment deraf internaliserer ind i mesothelin-udtrykkende celler og har en antigenbindende region, hvor den antistofbindende region inkluderer en HCDR 1, HCDR 2, HCDR 3, LCDR 1, LCDR 2 og LCDR 3, hvor: a) HCDR1 er SEQ ID NO: 5, b) HCDR2 er SEQ ID NO: 39, c) HCDR3 er SEQ ID NO: 71, d) LCDR1 er SEQ ID NO: 103, e) LCDR2 er SEQ ID NO: 133 og f) LCDR3 er SEQ ID NO: 169.
2. Antistof ifølge krav 1, som omfatter en aminosyresekvens for en variabel tung kæde ifølge SEQ ID NO: 212.
3. Antistof ifølge krav 1, som omfatter en aminosyresekvens for en variabel let kæde ifølge MF-T VL i tabel 4.
4. Antistof ifølge et hvilket som helst af kravene 1 til 3, som er et IgG.
5. Isoleret funktionelt fragment af et antistof ifølge et hvilket som helst af kravene 1-3, som er et Fab- eller scFv-antistoffragment.
6. Isoleret nukleinsyresekvens, der koder for en antigenbindende region af et humant antistof eller funktionelt fragment deraf ifølge et hvilket som helst af kravene 1-5.
7. Vektor, der omfatter en nukleinsyresekvens ifølge krav 6.
8. Isoleret celle, der omfatter en vektor ifølge krav 7.
9. Isoleret celle ifølge krav 9, hvor cellen er en bakterieeller mammaliacelle.
10. Farmaceutisk sammensætning, der omfatter et antistof eller et funktionelt fragment ifølge et hvilket som helst af kravene 1-5 og et farmaceutisk acceptabelt bæremateriale eller excipiens derfor.
11. Antistof eller fragment ifølge et hvilket som helst af kravene 1-5 til anvendelse som et lægemiddel.
12. Humant antistof ifølge et hvilket som helst af kravene 1-5, hvor det humane antistof er et syntetisk humant antistof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US437807P | 2007-11-26 | 2007-11-26 | |
PCT/EP2008/009756 WO2009068204A1 (en) | 2007-11-26 | 2008-11-19 | Anti-mesothelin antibodies and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2215121T3 true DK2215121T3 (da) | 2016-05-02 |
Family
ID=40351874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08855189.0T DK2215121T3 (da) | 2007-11-26 | 2008-11-19 | Anti-mesothelin-antistoffer og anvendelser deraf |
Country Status (31)
Country | Link |
---|---|
US (3) | US9023351B2 (da) |
EP (3) | EP3103814A1 (da) |
JP (3) | JP5608091B2 (da) |
KR (1) | KR101559599B1 (da) |
CN (2) | CN104151429B (da) |
AU (1) | AU2008329221B2 (da) |
BR (1) | BRPI0819909B8 (da) |
CA (1) | CA2706529C (da) |
CO (1) | CO6280409A2 (da) |
CR (1) | CR11456A (da) |
CU (1) | CU23833A3 (da) |
CY (1) | CY1117437T1 (da) |
DK (1) | DK2215121T3 (da) |
DO (1) | DOP2010000150A (da) |
EC (1) | ECSP10010191A (da) |
ES (1) | ES2569513T3 (da) |
GT (1) | GT201000148A (da) |
HK (2) | HK1148541A1 (da) |
HN (1) | HN2010001062A (da) |
HR (1) | HRP20160485T1 (da) |
HU (1) | HUE027358T2 (da) |
IL (1) | IL205681A0 (da) |
MA (1) | MA31862B1 (da) |
MX (1) | MX2010005603A (da) |
MY (1) | MY157164A (da) |
NZ (1) | NZ585551A (da) |
PL (1) | PL2215121T3 (da) |
SI (1) | SI2215121T1 (da) |
TN (1) | TN2010000234A1 (da) |
UA (1) | UA106036C2 (da) |
WO (1) | WO2009068204A1 (da) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA018396B1 (ru) * | 2007-10-01 | 2013-07-30 | Бристоль-Мейерз Сквибб Компани | Антитела человека, которые связывают мезотелин, и применение таких антител |
BRPI0819909B8 (pt) * | 2007-11-26 | 2021-05-25 | Bayer Ip Gmbh | anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica |
UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
PE20141114A1 (es) | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
TWI636793B (zh) | 2011-04-21 | 2018-10-01 | 西雅圖遺傳學公司 | 新穎結合劑-藥物接合物(ADCs)及其用途(二) |
US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
WO2014052064A1 (en) * | 2012-09-27 | 2014-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
BR112016014830A2 (pt) | 2013-12-23 | 2017-09-19 | Bayer Pharma AG | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp |
SG10201902850TA (en) | 2014-09-30 | 2019-04-29 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN108025084A (zh) | 2015-06-22 | 2018-05-11 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc) |
TW201718641A (zh) * | 2015-06-30 | 2017-06-01 | 偉東 姜 | 抗血管內皮生長因子受體2(vegfr2)抗體 |
JP6994456B2 (ja) * | 2015-08-21 | 2022-02-04 | カファ セラピューティクス リミテッド | 抗メソテリン完全ヒト抗体およびメソテリンを標的とする免疫エフェクター細胞 |
KR101782487B1 (ko) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
JP7082055B2 (ja) | 2015-12-22 | 2022-06-07 | ノバルティス アーゲー | 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体 |
CN109072195A (zh) | 2015-12-30 | 2018-12-21 | 诺华股份有限公司 | 具有增强功效的免疫效应细胞疗法 |
ES2888024T3 (es) * | 2016-02-15 | 2021-12-30 | Kanagawa Prefectural Hospital Organization | Reconocimiento de proteína similar a mucina de tipo membrana y aplicación clínica de la misma |
US20200281973A1 (en) | 2016-03-04 | 2020-09-10 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
MX2018011627A (es) | 2016-03-24 | 2019-01-10 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. |
KR20180134385A (ko) | 2016-04-15 | 2018-12-18 | 노파르티스 아게 | 선택적 단백질 발현을 위한 조성물 및 방법 |
RU2018146050A (ru) | 2016-05-27 | 2020-06-29 | Эббви Байотерапьютикс Инк. | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген |
WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法 |
US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
JP7217970B2 (ja) | 2016-10-07 | 2023-02-06 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を用いてt細胞受容体をリプログラミングするための組成物及び方法 |
WO2018098365A2 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
MY191926A (en) | 2016-12-01 | 2022-07-18 | Regeneron Pharma | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
MX2019007641A (es) | 2016-12-21 | 2019-09-09 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. |
EP3558386A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
US20210079057A1 (en) | 2017-06-13 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
JP6339283B1 (ja) | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Dna、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
EP3728316A1 (en) | 2017-12-19 | 2020-10-28 | F-Star Beta Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
WO2019124468A1 (ja) * | 2017-12-24 | 2019-06-27 | ノイルイミューン・バイオテック株式会社 | ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞 |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
TW202026006A (zh) | 2018-08-30 | 2020-07-16 | 美商Tcr2療法股份有限公司 | 使用融合蛋白進行tcr再程式化之組成物及方法 |
EP3897851A2 (en) | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
JP2022524449A (ja) * | 2019-03-14 | 2022-05-02 | モルフォシス・アーゲー | C5aRを標的とする抗体 |
AU2020242284A1 (en) | 2019-03-19 | 2021-09-16 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy for the treatment of cancer |
WO2020234114A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | A novel stable high concentration formulation for anetumab ravtansine |
WO2021021825A1 (en) * | 2019-07-29 | 2021-02-04 | Fred Hutchinson Cancer Research Center | Methods and compositions for inducing notch signaling in tumor microenvironments |
CA3164129A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
CN116019939A (zh) * | 2022-11-24 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 靶向msln的分子探针以及用途 |
CN117843793B (zh) * | 2024-03-07 | 2024-07-09 | 深圳真实生物医药科技有限公司 | 抗间皮素抗体、抗原结合片段及其用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質/(ポリ)ペプチドライブラリー |
US6083502A (en) * | 1996-01-05 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mesothelium antigen and methods and kits for targeting it |
US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
ES2255194T3 (es) * | 1997-12-01 | 2006-06-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos, que incluyen moleculas fv, e inmunoconjugados que presentan una afinidad de enlace elevada para la mesotelina y metodos para su utilizacion. |
ES2269105T3 (es) * | 1999-02-26 | 2007-04-01 | Pacific Northwest Research Institute | Metodos y composiciones para el diagnostico de carcinomas. |
DE60041119D1 (de) | 1999-07-20 | 2009-01-29 | Morphosys Ag | Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen |
EP2322560B1 (en) * | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
US20090047211A1 (en) | 2005-05-12 | 2009-02-19 | The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services | Anti-mesothelin antibodies useful for immunological assays |
PT1888643E (pt) | 2005-05-18 | 2015-01-14 | Morphosys Ag | Anticorpos anti-fec-gm e as respectivas utilizações |
AU2006252733A1 (en) * | 2005-06-02 | 2006-12-07 | Astrazeneca Ab | Antibodies directed to CD20 and uses thereof |
EA018396B1 (ru) * | 2007-10-01 | 2013-07-30 | Бристоль-Мейерз Сквибб Компани | Антитела человека, которые связывают мезотелин, и применение таких антител |
BRPI0819909B8 (pt) * | 2007-11-26 | 2021-05-25 | Bayer Ip Gmbh | anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica |
-
2008
- 2008-11-19 BR BRPI0819909A patent/BRPI0819909B8/pt active IP Right Grant
- 2008-11-19 JP JP2010535269A patent/JP5608091B2/ja active Active
- 2008-11-19 US US12/744,849 patent/US9023351B2/en active Active
- 2008-11-19 HU HUE08855189A patent/HUE027358T2/en unknown
- 2008-11-19 PL PL08855189T patent/PL2215121T3/pl unknown
- 2008-11-19 CA CA2706529A patent/CA2706529C/en active Active
- 2008-11-19 WO PCT/EP2008/009756 patent/WO2009068204A1/en active Application Filing
- 2008-11-19 EP EP16170412.7A patent/EP3103814A1/en not_active Withdrawn
- 2008-11-19 EP EP08855189.0A patent/EP2215121B1/en active Active
- 2008-11-19 ES ES08855189.0T patent/ES2569513T3/es active Active
- 2008-11-19 CN CN201410396441.8A patent/CN104151429B/zh active Active
- 2008-11-19 SI SI200831603A patent/SI2215121T1/sl unknown
- 2008-11-19 CN CN200880125390.8A patent/CN101952319B/zh active Active
- 2008-11-19 DK DK08855189.0T patent/DK2215121T3/da active
- 2008-11-19 UA UAA201008006A patent/UA106036C2/uk unknown
- 2008-11-19 KR KR1020107011375A patent/KR101559599B1/ko active IP Right Grant
- 2008-11-19 EP EP13168583.6A patent/EP2634196A1/en not_active Ceased
- 2008-11-19 AU AU2008329221A patent/AU2008329221B2/en active Active
- 2008-11-19 NZ NZ585551A patent/NZ585551A/en unknown
- 2008-11-19 MX MX2010005603A patent/MX2010005603A/es active IP Right Grant
- 2008-11-19 MY MYPI2010002379A patent/MY157164A/en unknown
-
2010
- 2010-05-11 IL IL205681A patent/IL205681A0/en active IP Right Grant
- 2010-05-20 GT GT201000148A patent/GT201000148A/es unknown
- 2010-05-20 DO DO2010000150A patent/DOP2010000150A/es unknown
- 2010-05-21 CO CO10061059A patent/CO6280409A2/es not_active Application Discontinuation
- 2010-05-21 CU CU2010000098A patent/CU23833A3/es active IP Right Grant
- 2010-05-21 CR CR11456A patent/CR11456A/es unknown
- 2010-05-21 HN HN2010001062A patent/HN2010001062A/es unknown
- 2010-05-21 EC EC2010010191A patent/ECSP10010191A/es unknown
- 2010-05-24 MA MA32865A patent/MA31862B1/fr unknown
- 2010-05-25 TN TN2010000234A patent/TN2010000234A1/fr unknown
-
2011
- 2011-03-16 HK HK11102654.0A patent/HK1148541A1/xx unknown
-
2014
- 2014-07-03 JP JP2014137893A patent/JP2014221064A/ja active Pending
-
2015
- 2015-02-10 HK HK15101434.5A patent/HK1200856A1/xx unknown
- 2015-03-11 US US14/645,411 patent/US20150259433A1/en not_active Abandoned
-
2016
- 2016-04-27 CY CY20161100353T patent/CY1117437T1/el unknown
- 2016-05-06 HR HRP20160485TT patent/HRP20160485T1/hr unknown
-
2018
- 2018-03-05 JP JP2018038254A patent/JP6717869B2/ja active Active
- 2018-03-05 US US15/911,748 patent/US20180258181A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2215121T3 (da) | Anti-mesothelin-antistoffer og anvendelser deraf | |
US9371396B2 (en) | Anti-CD22 anti-idiotypic antibodies and uses thereof | |
KR101931820B1 (ko) | 항―c4.4a 항체 및 그의 용도 | |
KR20220025938A (ko) | 항-pd-1 항체 및 이의 용도 | |
JP2005536181A (ja) | 新規抗igf−ir抗体およびその使用 | |
CN112533955A (zh) | 抗b7-h3抗体 | |
CN109219446B (zh) | Alk7结合蛋白及其用途 | |
CN112243443A (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
US9403909B2 (en) | Anti-MST1R antibodies and uses thereof | |
JP2024500512A (ja) | 抗b7-h3抗体およびその使用 | |
CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
CN115843256A (zh) | 抗erbb3抗体或其抗原结合片段及其医药用途 |